Wolverine Trading’s Ultragenyx Pharmaceutical RARE Stock Holding History

Wolverine Trading’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$823K	Buy	27,100 +21,100	+352%	+$633K	﹤0.01%	3112
2025 Q2	$219K	Buy	+6,000	New	+$216K	﹤0.01%	3817
2025 Q1	–	Sell	-8,200	Closed	-$347K	–	5619
2024 Q4	$347K	Sell	8,200 -7,300	-47%	-$362K	﹤0.01%	3859
2024 Q3	$844K	Buy	+15,500	New	+$790K	﹤0.01%	2534
2024 Q2	–	Sell	-7,400	Closed	-$346K	–	5084
2024 Q1	$346K	Buy	+7,400	New	+$349K	﹤0.01%	3206
2023 Q4	–	Sell	-9,700	Closed	-$346K	–	5071
2023 Q3	$346K	Buy	9,700 +1,000	+11%	+$39.6K	﹤0.01%	3153
2023 Q2	$406K	Sell	8,700 -100	-1%	-$4.64K	﹤0.01%	2805
2023 Q1	$340K	Buy	+8,800	New	+$378K	﹤0.01%	2894
2021 Q4	–	Sell	-2,500	Closed	-$215K	–	6648
2021 Q3	$215K	Buy	+2,500	New	+$226K	﹤0.01%	5225

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Wolverine Trading's RARE Position: Q3 2025 in Review

Wolverine Trading increased its Ultragenyx Pharmaceutical (RARE) stake by 67% in Q3 2025, buying an estimated $126K and bringing the position to 10,494 shares worth $319K. The position accounts for ﹤0.01% of the portfolio, ranked #4291.

Wolverine Trading first reported a position in RARE in Q2 2020 and has held it in 5 quarters since. The position peaked at $338K in Q2 2020. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

Wolverine Trading held 10,494 shares of Ultragenyx Pharmaceutical worth $319K as of Q3 2025.
Wolverine Trading bought 4,201 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $126K.
Ultragenyx Pharmaceutical made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #4291 holding.
Wolverine Trading first reported a position in Ultragenyx Pharmaceutical in Q2 2020 and has held it in 5 quarters since.
Wolverine Trading's Ultragenyx Pharmaceutical position peaked at $338K in Q2 2020.
302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.